In 2011, Cystic Fibrosis Foundation advocates worked to advance cystic fibrosis research and help ensure access to treatment and care for people with the disease.
In a strong show of support for the CF community, the U.S. Senate Appropriations Committee recently expressed the importance of innovative cystic fibrosis research in a spending bill, which is part of the federal budget under consideration right now in Congress.
The Cystic Fibrosis Foundation's successful business model was at the center of a congressional briefing in Washington, D.C., today, which focused on strategies for jump-starting drug development for rare diseases.
A new law that allows patients with rare diseases to participate in clinical trials without losing eligibility for public health care benefits went into effect yesterday. The bill, known as the “Improving Access to Clinical Trials Act” (IACT), was championed by the Cystic Fibrosis Foundation and signed into law in October 2010.